2.86 USD
+0.14
5.15%
At close Apr 2, 4:00 PM EDT
After hours
2.82
-0.04
1.40%
1 day
5.15%
5 days
0.35%
1 month
-7.14%
3 months
-17.10%
6 months
-4.67%
Year to date
-17.10%
1 year
-0.69%
5 years
-94.88%
10 years
-94.88%
 

About: CureVac NV is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Employees: 1,100

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

12% more call options, than puts

Call options by funds: $322K | Put options by funds: $288K

1.46% less ownership

Funds ownership: 4.97% [Q3] → 3.5% (-1.46%) [Q4]

6% less funds holding

Funds holding: 80 [Q3] → 75 (-5) [Q4]

13% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 24

19% less capital invested

Capital invested by funds: $32.8M [Q3] → $26.6M (-$6.19M) [Q4]

24% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 17

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$16
459%
upside
Avg. target
$16
459%
upside
High target
$16
459%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
JMP Securities
Roy Buchanan
24% 1-year accuracy
6 / 25 met price target
459%upside
$16
Market Outperform
Reiterated
14 Feb 2025

Financial journalist opinion

Based on 4 articles about CVAC published over the past 30 days

Positive
Market Watch
5 days ago
CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.
CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit
Positive
Benzinga
5 days ago
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac N.V. CVAC on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
Positive
Reuters
6 days ago
European Patent Office declares CureVac mRNA patent valid
The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.
European Patent Office declares CureVac mRNA patent valid
Neutral
Accesswire
6 days ago
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP 3 708 668 B1 is scheduled for July 1, 2025, before the Regional Court Düsseldorf Confirming validity of patent in its amended form marks major milestone in broader patent litigation in Germany, recognizing CureVac's pioneering mRNA innovation TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / March 27, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the European Patent Office (EPO) has confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
Neutral
Accesswire
1 month ago
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of the broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / February 18, 2025 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its recognition as a Top 100 Global Innovator in the Innovation Momentum 2025 report by LexisNexis®.
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators
Positive
Seeking Alpha
2 months ago
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVGBM resectable GBM data release in 2nd half of 2025 and possible phase 2 study initiation in 2nd half of 2026. The company is also developing a vaccine for squamous NSCLC, with an IND filing expected in the 1st half of 2025 and phase 1 study initiation in the 2nd half of 2025.
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
Positive
MarketBeat
3 months ago
2 Small-Cap Stocks Set to Shine in a Bull Market
Small-cap stocks often experience outsized gains during bullish markets. Their smaller market capitalizations and growth-oriented profiles make them more sensitive to improving economic conditions, where rising investor confidence drives capital toward higher-risk, higher-reward opportunities.
2 Small-Cap Stocks Set to Shine in a Bull Market
Neutral
Zacks Investment Research
4 months ago
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?
Investors need to pay close attention to CureVac (CVAC) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?
Neutral
Seeking Alpha
4 months ago
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
CureVac N.V. (NASDAQ:CVAC ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications and Investor Relations Alexander Zehnder - Chief Executive Officer Axel Malkomes - Chief Financial Officer Myriam Mendila - Chief Development Officer Rudiger Wolff - Senior Vice President of Finance Conference Call Participants Charlie Yang - Bank of America Merrill Lynch CJ Yeh - Leerink Partners Roy Buchanan - Citizens JMP Operator Greetings and welcome to the CureVac Financial Results and Business Update for the Third Quarter and First Nine Months of 2024 Conference Call.
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
Neutral
Accesswire
4 months ago
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025 New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccines Positive Phase 2 data from seasonal influenza program licensed to GSK demonstrated strong immune responses against challenging influenza B as well as A strains; program progressing to Phase 3, which will be associated with significant milestone payment Corporate redesign on track with 30% workforce reduction, expected to yield significant annual cost savings from 2025 onwards and increase operational agility Appointment of seasoned industry executive Axel Malkomes as new CFO effective November 11, enhancing financial leadership and strategic execution CureVac to host conference call and webcast today at 9 a.m. EST / 3 p.m.
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Charts implemented using Lightweight Charts™